loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Deferoxamine Mesylate

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Deferoxamine Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,014Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mitem Pharma Acquires Rights To Desferal
    Mitem Pharma Acquires Rights To Desferal

    25 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240924810630/en

    BUSINESSWIRE
    25 Sep 2024
    Share Share
    Challenges Of Developing And Facilitating Access To New Sickle Cell Disease
    Challenges Of Developing And Facilitating Access To New Sickle Cell Disease

    15 Oct 2020

    // Joshua Cohen FORBES

    https://www.forbes.com/sites/joshuacohen/2020/10/15/challenges-of-developing-and-facilitating-access-to-new-sickle-cell-disease-therapies-case-of-the-deferoxamine-patch/#4137fbbc4289

    Joshua Cohen FORBES
    15 Oct 2020
    Share Share
    Theris Medical Launches Patient Enrollment for “Orphan Drug” Clinical Trial
    Theris Medical Launches Patient Enrollment for “Orphan Drug” Clinical Trial

    16 Sep 2020

    // WEBWIRE

    https://www.webwire.com/ViewPressRel.asp?aId=264034

    WEBWIRE
    16 Sep 2020
    Share Share
    Enforcement Report - Week of October 11, 2017
    Enforcement Report - Week of October 11, 2017

    11 Oct 2017

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-11-2017-1507696514.pdf

    FDA
    11 Oct 2017
    Share Share
    Walgreens Infusion Services, Ongoing Class III recall of Deferoxamine various strengths in normal saline because of Lack of sterility assurance.
    Walgreens Infusion Services, Ongoing Class III recall of Deferoxamine various strengths in normal saline because of Lack of sterility assurance.

    28 Jan 2015

    // FDA

    http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0370-2015&w=01282015&lang=eng

    FDA
    28 Jan 2015
    Share Share